立方制药 (003020.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1.6B	1.6B	1.5B	1.9B	2.6B
Cost of Revenue	539.9M	550.8M	468.3M	922.2M	1.6B
Gross Profit	1.0B	1.0B	1.1B	978.6M	964.3M
Operating Expenses
R&D Expense	110.1M	110.8M	91.8M	85.0M	73.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	71.7M	70.2M	81.6M	62.0M	59.1M
Selling & Marketing Expense	656.8M	654.2M	692.1M	598.5M	616.4M
Other Expenses	—	—	—	—	—
Total Operating Expenses	864.7M	860.6M	887.7M	760.4M	761.7M
Cost and Expenses	1.4B	1.4B	1.4B	1.7B	2.4B
Operating Income (EBIT)	179.8M	182.1M	177.7M	255.3M	240.1M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	178.9M	181.8M	171.8M	257.4M	239.8M
Income Tax Expense	19.4M	18.2M	19.3M	23.5M	30.6M
Bottom Line
Net Income	162.2M	165.2M	160.6M	226.7M	209.2M
Earnings from Cont. Ops	159.5M	163.6M	152.5M	233.9M	209.2M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	162.2M	165.2M	160.6M	226.7M	209.2M
Per Share
Basic EPS	CN¥0.86	CN¥0.87	CN¥0.84	CN¥1.18	CN¥1.33
Diluted EPS	CN¥0.86	CN¥0.87	CN¥0.84	CN¥1.18	CN¥1.33
Revenue Per Share	CN¥8.35	CN¥8.18	CN¥7.94	CN¥9.90	CN¥16.39
Shares
Basic Shares Outstanding	185.7M	189.9M	191.2M	192.1M	157.3M
Diluted Shares Outstanding	185.7M	189.9M	191.2M	192.1M	157.3M
Profitability Metrics
EBITDA	—	269.5M	256.0M	293.3M	268.2M
D&A	—	87.4M	78.2M	38.0M	28.1M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026